20577-73-5

Basic information

• Product Name: METHYL 2,4-DIOXO-4-PHENYLBUTANOATE
• Synonyms: METHYL 2,4-DIOXO-4-PHENYLBUTANOATE;AKOS BBS-00001161;SALOR-INT L499196-1EA;alpha,gamma-Dioxobenzenebutanoic acid methyl ester;Methyl 2,4-dioxo-4-phenylbutyrate;Methyl 4-phenyl-2,4-dioxobutanoate;Methyl benzoylpyruvate;NSC 208703
• CAS NO: 20577-73-5
• Molecular Formula: C₁₁H₁₀O₄
• Molecular Weight: 206.19
• Mol File: 20577-73-5.mol
• Article Data: 18

Chemical Properties

• Melting Point: 59-60°C
• Boiling Point: 335.6 °C at 760 mmHg
• Flash Point: 149 °C
• Appearance: /
• Density: 1.205 g/cm³
• Vapor Pressure: 2.89E-05mmHg at 25°C
• Refractive Index: 1.56
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chlroform (Slightly), DMSO (Slightly)
• PKA: 5.95±0.23(Predicted)
• CAS DataBase Reference: METHYL 2,4-DIOXO-4-PHENYLBUTANOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2,4-DIOXO-4-PHENYLBUTANOATE(20577-73-5)
• EPA Substance Registry System: METHYL 2,4-DIOXO-4-PHENYLBUTANOATE(20577-73-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 20577-73-5(Hazardous Substances Data)

Usage

Uses

Methyl 2,4-Dioxo-4-phenylbutanoate can be used for antimicrobial activity.

InChI:InChI=1/C11H10O4/c1-15-11(14)10(13)7-9(12)8-5-3-2-4-6-8/h2-7,12H,1H3

Upstream product

• 56795-82-5 5-phenyl-2-methoxyfurane 
• 67-56-1 methanol 
• 98-86-2 acetophenone 
• 95-92-1 oxalic acid diethyl ester 
• 124-41-4 sodium methylate 
• 553-90-2 Dimethyl oxalate 
• 88-15-3 2-Acetylthiophene 

Downstream Products

• 5817-92-5 2,4-dioxo-4-phenylbutanoic acid 
• 78051-28-2 methyl 4-oxo-4-phenyl-2-[2-(phenylcarbonyl)hydrazinylidene]butanoate 
• 76051-12-2 methyl 2-(isopropylphenylhydrazono)-4-phenyl-4-oxobutyrate 
• 76051-11-1 (Z)-2-(N'-Ethyl-N'-phenyl-hydrazino)-4-oxo-4-phenyl-but-2-enoic acid methyl ester 
• 125103-79-9 2-Oxo-3-[2-oxo-2-phenyl-eth-(E)-ylidene]-1,2,3,4-tetrahydro-quinoxaline-6-carbonitrile 
• 125179-77-3 methyl 4-oxo-4-phenyl-2-p-bromophenylamino-Z-2-butenoate 
• 76051-07-5 (Z)-2-(N'-Methyl-N'-p-tolyl-hydrazino)-4-oxo-4-phenyl-but-2-enoic acid methyl ester 
• 76051-06-4 (Z)-2-[N'-(4-Methoxy-phenyl)-N'-methyl-hydrazino]-4-oxo-4-phenyl-but-2-enoic acid methyl ester 
• 76051-10-0 (Z)-2-[N'-Methyl-N'-(4-nitro-phenyl)-hydrazino]-4-oxo-4-phenyl-but-2-enoic acid methyl ester 
• 125179-78-4 (Z)-2-(2-Cyano-phenylamino)-4-oxo-4-phenyl-but-2-enoic acid methyl ester 
• 152449-34-8 (Z)-3-phenacylidene-1-phenyl-1,2,3,4-tetrahydroquinoxalin-2-one 
• 108576-31-4 4-benzoyl-3-hydroxy-1-p-tolyl-5-phenyl-2,5-dihydro-2-pyrrolone 

Relevant articles and documents

Novel isoxazole derivatives as potential antiparkinson agents: synthesis, evaluation of monoamine oxidase inhibitory activity and docking studies

Selective monoamine oxidase B inhibitors are potential drug candidates for the treatment of Parkinson’s disease. A series of phenyl substituted isoxazole carbohydrazides was designed by structural modification of isocarboxazid, a nonselective MAO inhibito

Novel N-Substituted oseltamivir derivatives as potent influenza neuraminidase inhibitors: Design, synthesis, biological evaluation, ADME prediction and molecular docking studies

The discovery of novel potent neuraminidase (NA) inhibitors remains an attractive approach for treating infectious diseases caused by influenza. In this study, we describe the design and synthesis of novel N-substituted oseltamivir derivatives for probing the 150-cavity which is nascent to the activity site of NA. NA inhibitory studies showed that new derivatives demonstrated the inhibitory activity with IC50 values at nM level against NA of a clinical influenza virus strain. Moreover, the in silico ADME predictions showed that the selected compounds had comparable properties with oseltamivir carboxylate, which demonstrated the druggablity of these derivatives. Furthermore, molecular docking studies showed that the most potent compound 6f and 10i could adopt different modes of binding interaction with NA, which may provide novel solutions for treating oseltamivir-resistant influenza. Based on the research results, we consider that compounds 6f and 10i have the potential for further studies as novel antiviral agents.

Synthetic method of OLED material intermediate benzoyl pyrimidine compound

The invention discloses a synthetic method of an OLED material intermediate benzoyl pyrimidine compound. The synthetic method comprises the following steps: mixing alkali, a solvent I as well as substituent acetophenone and oxalic acid diester which are u